MedPath
HSA Approval

QUPRON TABLETS 250 mg

SIN09569P

QUPRON TABLETS 250 mg

QUPRON TABLETS 250 mg

December 5, 1997

ZYFAS PHARMA PTE LTD

ZYFAS PHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantZYFAS PHARMA PTE LTD
Licence HolderZYFAS PHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**【DOSAGE AND ADMINISTRATION】** 1. Usually for adults, administer 250~500mg at meal intervals twice a day. In severe mixed infections, administer up to 750mg twice a day. In acute infections, usually treat for 5 to 10 days. After disappearance of symptoms, further administration is required at least for 3 days. 2. In patients with severe renal disorder, it should be administered according to the following dosage and administration. ![Qupron Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/cb50c9c812e5aa27cea47055d9abe5f4.png) When only the concentration of serum creatinine clearance is known, the patient’s creatinine clearance can be estimated by using the following formulas: ![Qupron Dosage Formula 1](https://cdn.medpath.com/drug/dosage/20240520/f4e0acb69660f33421b61e8a503ca492.png) In patient with severe cardiac failure and infections, 750mg can be administered once, but careful monitoring is required and the ciprofloxacin concentration should be periodically estimated. At that time, the peak serum concentration (obtained 1~2 hours after administration) should range from 2~4mcg/ml. 3. Dosage may be adjusted according to causative organisms and severity of symptom.

ORAL

Medical Information

**【INDICATIONS】** 1. Susceptible organisms : E. coli, Shigella, Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, hafnia, proteus (Indole positive & negative). Pseudomonas, Neisseria, Acinetobacter, Streptococcus, Chlamydia, Staphylococcus, Corynebacterium, Bacteroides, Clostridium 2. Indications Respiratory infections, infections of oral cavity, teeth and jaw, infections of ear, nose and throat, infections of kidney or urinary passages, genital infections containing gonorrhea, gastrointestinal infections, infection and wound of soft tissue, infections of bone and joint, infections in gynecological and obstetric field, septicemia, cerebromeningitis, peritonitis, ophthalmologic infections and infections in bile secretory duct.

**【PRECAUTIONS】** 1. Contraindications 1. Patients previously found hypersensitive to it. 2. Pregnancy and nursing woman 3. Children and infants 4. Patients with hepatic disorder

J01MA02

ciprofloxacin

Manufacturer Information

ZYFAS PHARMA PTE. LTD.

SHIN POONG PHARMACEUTICAL CO LTD

Active Ingredients

CIPROFLOXACIN HCl EQV CIPROFLOXACIN

250 mg

Ciprofloxacin

Documents

Package Inserts

Qupron PI.pdf

Approved: May 7, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

QUPRON TABLETS 250 mg - HSA Approval | MedPath